Selecta Biosciences (NASDAQ:SELB) Releases Earnings Results, Beats Expectations By $0.09 EPS

Selecta Biosciences (NASDAQ:SELB – Get Rating) issued its earnings results on Thursday. The company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.09, Fidelity Earnings reports. Selecta Biosciences had a return on equity of 21.22% and a net margin of 24.85%. During the same period in the prior year, the business earned ($0.04) EPS.

Selecta Biosciences Price Performance

Shares of NASDAQ:SELB traded up $0.48 during trading on Friday, reaching $2.36. The stock had a trading volume of 6,539,735 shares, compared to its average volume of 1,652,469. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.31 and a current ratio of 3.31. Selecta Biosciences has a 1-year low of $0.65 and a 1-year high of $4.70. The stock has a market cap of $358.27 million, a PE ratio of 236.00 and a beta of 1.04. The business has a fifty day moving average price of $1.39 and a 200-day moving average price of $1.44.

Insider Activity at Selecta Biosciences

In other Selecta Biosciences news, Director Carrie Smith Cox bought 130,000 shares of the company’s stock in a transaction dated Monday, June 13th. The stock was acquired at an average price of $1.15 per share, with a total value of $149,500.00. Following the completion of the acquisition, the director now directly owns 212,881 shares of the company’s stock, valued at $244,813.15. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Selecta Biosciences news, Director Carrie Smith Cox bought 130,000 shares of the company’s stock in a transaction dated Monday, June 13th. The stock was acquired at an average price of $1.15 per share, with a total value of $149,500.00. Following the completion of the acquisition, the director now directly owns 212,881 shares of the company’s stock, valued at $244,813.15. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Timothy C. Barabe bought 50,000 shares of the company’s stock in a transaction dated Monday, May 9th. The shares were acquired at an average cost of $0.77 per share, with a total value of $38,500.00. Following the acquisition, the director now directly owns 250,013 shares of the company’s stock, valued at $192,510.01. The disclosure for this purchase can be found here. 30.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Selecta Biosciences

A number of large investors have recently modified their holdings of SELB. Eqis Capital Management Inc. purchased a new stake in shares of Selecta Biosciences during the first quarter worth $30,000. Beacon Pointe Advisors LLC acquired a new position in shares of Selecta Biosciences during the 1st quarter valued at about $33,000. Mirabella Financial Services LLP acquired a new position in shares of Selecta Biosciences during the 1st quarter valued at about $82,000. XTX Topco Ltd boosted its position in shares of Selecta Biosciences by 261.9% during the 1st quarter. XTX Topco Ltd now owns 121,614 shares of the company’s stock valued at $150,000 after acquiring an additional 88,014 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Selecta Biosciences by 213.0% during the 1st quarter. Renaissance Technologies LLC now owns 1,490,400 shares of the company’s stock valued at $1,833,000 after acquiring an additional 1,014,200 shares during the last quarter. Hedge funds and other institutional investors own 72.62% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on SELB shares. StockNews.com downgraded Selecta Biosciences from a “buy” rating to a “hold” rating in a research note on Saturday, May 14th. HC Wainwright lowered their price target on Selecta Biosciences from $6.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, June 21st. SVB Leerink initiated coverage on Selecta Biosciences in a research report on Monday, June 6th. They set an “outperform” rating and a $7.00 price target on the stock. Needham & Company LLC lowered their price target on Selecta Biosciences from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Tuesday, June 14th. Finally, TheStreet upgraded Selecta Biosciences from a “d” rating to a “c-” rating in a research report on Wednesday, May 25th. One investment analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, Selecta Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $5.33.

Selecta Biosciences Company Profile

(Get Rating)

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia.